Findings

What do systematic reviews say?

4,678 questions · 4,859 findings · 283 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,225 · 25.2%GRADE not reported 215 · 4.4%Very low 1,241 · 25.5%Low 1,210 · 24.9%Moderate 776 · 16%High 192 · 4%

Summary of findings ‐ Supplemental breast milk vs control

Any adverse outcome · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age) up to maximum of 44…

The review found no eligible studies for this question.

1 finding from 1 review

Breastfeeding or breast milk for procedural pain in neonates 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ Supplemental breast milk vs control

Heart rate · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age) up to maximum of 44…

1 finding from 1 review

Breastfeeding or breast milk for procedural pain in neonates 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 336 participants
Low

Summary of findings ‐ Supplemental breast milk vs control

Duration of crying (seconds) · term newborns (≥ 37 completed weeks' postmenstrual age) and preterm infants (< 37 completed weeks' postmenstrual age) up to maximum of 44…

1 finding from 1 review

Breastfeeding or breast milk for procedural pain in neonates 2023 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 1283 participants
Moderate

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

FEV1 % predicted: relative change from baseline · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

FEV1 % predicted: absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Adverse events: occurring in at least 10% of cavosonstat treated participants · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Time to first pulmonary exacerbation · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Survival · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Very low

Summary of findings ‐ monotherapy: cavosonstat vs placebo

Quality of life: total score · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings table ‐ Limited sternotomy vs full median sternotomy

All‐cause mortality · participants requiring aortic valve replacement

Summary of findings table ‐ Limited sternotomy showed no clear difference in mortality compared with full sternotomy (low certainty).

1 finding from 1 review

Limited versus full sternotomy for aortic valve replacement 2023 · Cochrane Headline outcomes only
RR 0.93 [0.45, 1.94]
10 studies · 985 participants
Low

Summary of findings table ‐ Limited sternotomy vs full median sternotomy

Cardiopulmonary bypass time · participants requiring aortic valve replacement

1 finding from 1 review

Limited versus full sternotomy for aortic valve replacement 2023 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 1043 participants
Very low

Summary of findings table ‐ Limited sternotomy vs full median sternotomy

Aortic cross‐clamp time · participants requiring aortic valve replacement

1 finding from 1 review

Limited versus full sternotomy for aortic valve replacement 2023 · Cochrane Headline outcomes only
no estimate extracted
12 studies · 1235 participants
Very low

Summary of findings table ‐ Limited sternotomy vs full median sternotomy

Postoperative blood loss (mL) · participants requiring aortic valve replacement

1 finding from 1 review

Limited versus full sternotomy for aortic valve replacement 2023 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 767 participants
Moderate

Summary of findings table ‐ Limited sternotomy vs full median sternotomy

Pain scores, measured in various ways at a median of 2 days' · participants requiring aortic valve replacement

1 finding from 1 review

Limited versus full sternotomy for aortic valve replacement 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 649 participants
Low

Summary of findings table ‐ Limited sternotomy vs full median sternotomy

Quality of life, · participants requiring aortic valve replacement

1 finding from 1 review

Limited versus full sternotomy for aortic valve replacement 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 624 participants
Low

Summary of findings table ‐ Limited sternotomy vs full median sternotomy

Index admission costs · participants requiring aortic valve replacement

1 finding from 1 review

Limited versus full sternotomy for aortic valve replacement 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 492 participants
Low

Summary of findings table ‐ routine monitoring vs no routine monitoring of gastric residual

Risk of necrotising enterocolitis stage ≥ 2 · preterm infants

Summary of findings table ‐ routine monitoring showed no clear difference in risk of necrotising enterocolitis stage ≥ 2 compared with no routine monitoring of gastric residual (moderate certainty).

1 finding from 1 review

Routine monitoring of gastric residual for prevention of necrotising enterocolitis in preterm infants 2023 · Cochrane Headline outcomes only
RR 1.08 [0.46, 2.57]
4 studies · 334 participants
Moderate

Summary of findings table ‐ routine monitoring vs no routine monitoring of gastric residual

Time to achieve full enteral feeding (days) · preterm infants

1 finding from 1 review

Routine monitoring of gastric residual for prevention of necrotising enterocolitis in preterm infants 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 334 participants
Moderate

Summary of findings table ‐ routine monitoring vs no routine monitoring of gastric residual

Days to regain birth weight · preterm infants

1 finding from 1 review

Routine monitoring of gastric residual for prevention of necrotising enterocolitis in preterm infants 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
Low